IntegraGen is currently conducting research in the field of oncology related to the identification of biomarkers which can provide clinicians with insight on the potential efficacy of drug therapies directed towards metastatic colorectal cancer (mCRC) and the prognosis of patients diagnosed with hepatocellular carcinoma. These discoveries are a result of collaborative partnerships the company has with with leading academic researchers in the field of oncology.
For metastatic colorectal cancer, Integregan is working to develop a predictive test based on the biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR (Epidermal Growth Factor Receptor) monoclonal antibody therapy response in wild-type KRAS patients with mCRC .1 This effort is a result of original research led by Pierre Laurent-Puig, M.D., Ph.D., Professor, Department of Genetics and head of the Clinical Oncogenetic Unit, European Georges Pompidou Hospital, University Paris Descartes, Paris, France. A test based on this biomarker would be intended to allow for a more personalized approach to cancer care, sparing patients who would not likely benefit from anti-EGFR agents from associated toxicities while also preventing the loss of time and opportunity to receive other treatment options which may be more appropriate
IntegraGen is also developing a second series of biomarkers which have been shown to be prognostic for outcomes in patients with hepatocelluar carcinoma (liver cancer).2 This effort is a result of original research by Jessica Zucman-Rossi, M.D., Ph.D., Professor of Medicine,Oncology, University Paris Descartes, Hopital Européen Georges Pompidou and Head of the INSERM unit on Functional Genomics of Solid Tumors in Paris. By studying the expression of genes, IntegraGen aims to to better predict survival outcomes and the potential for cancer recurrence in patients with liver cancer and to identify differing subgroups of patients where surgery and targeted therapies are more effective.